Bevacizumab, approved by the FDA in 2004 and widely used in anti-cancer therapy [16], is a class of monoclonal antibodies against VEGF and is rarely used alone because of a lack of obvious efficacy, but it is mostly combined with platinum-based chemotherapeutics, which inevitably leads to a variety of adverse effects [48,49]. Here, VEGFA is linked to cancer.